Leerink Partnrs Has Negative Forecast for Geron Q1 Earnings

Geron Co. (NASDAQ:GERN) – Analysts at Leerink Partnrs reduced their Q1 2025 earnings estimates for shares of Geron in a research note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst F. Khurshid now forecasts that the biopharmaceutical company will post earnings per share of ($0.04) for the quarter, down from their previous estimate of ($0.03). The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron’s Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.10) EPS and FY2026 earnings at $0.05 EPS.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). The firm had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%.

GERN has been the topic of several other reports. Stifel Nicolaus cut their price objective on shares of Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday. HC Wainwright downgraded Geron from a “buy” rating to a “neutral” rating in a research note on Wednesday. Scotiabank dropped their price objective on shares of Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a report on Thursday. B. Riley lowered shares of Geron from a “buy” rating to a “neutral” rating and cut their target price for the company from $3.50 to $2.00 in a research report on Thursday. Finally, Barclays reiterated an “overweight” rating and issued a $4.00 price target (down from $9.00) on shares of Geron in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.68.

Geron Price Performance

Shares of NASDAQ GERN opened at $1.74 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The company’s 50-day moving average is $2.97 and its 200 day moving average is $3.80. The stock has a market capitalization of $1.05 billion, a P/E ratio of -5.44 and a beta of 0.53. Geron has a 1 year low of $1.46 and a 1 year high of $5.34.

Hedge Funds Weigh In On Geron

Several institutional investors and hedge funds have recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new stake in Geron in the fourth quarter valued at approximately $28,000. Integrated Wealth Concepts LLC acquired a new stake in Geron in the fourth quarter valued at $36,000. GF Fund Management CO. LTD. acquired a new stake in shares of Geron during the 4th quarter worth about $45,000. Readystate Asset Management LP acquired a new position in shares of Geron in the 3rd quarter valued at $58,000. Finally, Rovin Capital UT ADV purchased a new position in shares of Geron during the third quarter worth about $62,000. 73.71% of the stock is currently owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.